United States securities and exchange commission logo




                                                                                
                          April 2, 2024

       Angelos M. Stergiou, M.D., ScD h.c.
       President and Chief Executive Officer
       SELLAS Life Sciences Group, Inc.
       7 Times Square, Suite 2503
       New York, New York 10036

                                                        Re: SELLAS Life 
Sciences Group, Inc.
                                                            Registration 
Statement on Form S-3
                                                            Filed March 28, 
2024
                                                            File No. 333-278337

       Dear Angelos M. Stergiou:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Chris 
Edwards at 202-551-6761 with any questions.



                                                                                
                          Sincerely,

                                                                                
                          Division of Corporation Finance
                                                                                
                          Office of Life Sciences
       cc:                                              Daniel A. Bagliebter, 
Esq.